145 related articles for article (PubMed ID: 31414399)
21. Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.
Sargos P; Ferretti L; Gross-Goupil M; Orre M; Cornelis F; Henriques de Figueiredo B; Houédé N; Merino C; Roubaud G; Dallaudiére B; Richaud P; Fléchon A
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):220-6. PubMed ID: 24796290
[TBL] [Abstract][Full Text] [Related]
22. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
Feneley MR; Gillatt DA; Hehir M; Kirby RS
Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics of 13 neuroendocrine prostate cancer patients].
Zhang WH; Si TG; Yang XL; Yang B; Liu CF; Yu HP; Xing WG; Guo Z
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1316-1319. PubMed ID: 28482433
[No Abstract] [Full Text] [Related]
25. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
[TBL] [Abstract][Full Text] [Related]
26. The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
Pósfai B; Kuthi L; Varga L; Laczó I; Révész J; Kránicz R; Maráz A
Anticancer Res; 2018 Jun; 38(6):3243-3254. PubMed ID: 29848671
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
[TBL] [Abstract][Full Text] [Related]
29. Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series.
Suzuki K; Terakawa T; Jimbo N; Inaba R; Nakano Y; Fujisawa M
Anticancer Res; 2020 Jun; 40(6):3519-3526. PubMed ID: 32487653
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine cells in tumour growth of the prostate.
Abrahamsson PA
Endocr Relat Cancer; 1999 Dec; 6(4):503-19. PubMed ID: 10730904
[TBL] [Abstract][Full Text] [Related]
31. [Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels].
Feria-Bernal G; García-Gonzalez VM; Figueroa-Granados V; Martinez-Benítez B; Uribe-Uribe NO
Gac Med Mex; 2006; 142(6):441-6. PubMed ID: 17201105
[TBL] [Abstract][Full Text] [Related]
32. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers.
Rubin MA; Bristow RG; Thienger PD; Dive C; Imielinski M
Mol Cell; 2020 Nov; 80(4):562-577. PubMed ID: 33217316
[TBL] [Abstract][Full Text] [Related]
33. Dilemmas in Diagnosis and Management of Gastroenteropancreatic Mixed Neuroendocrine Non-neuroendocrine Neoplasms: First Single-Centre Report from India.
Desai GS; Pande P; Shah RC; Jagannath P
J Gastrointest Cancer; 2020 Mar; 51(1):102-108. PubMed ID: 30784017
[TBL] [Abstract][Full Text] [Related]
34. Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.
Hu J; Han B; Huang J
Arch Pathol Lab Med; 2020 Mar; 144(3):320-325. PubMed ID: 31644322
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer and neuroendocrine differentiation.
Tan MO; Karaoğlan U; Celik B; Ataoğlu O; Biri H; Bozkirli I
Int Urol Nephrol; 1999; 31(1):75-82. PubMed ID: 10408306
[TBL] [Abstract][Full Text] [Related]
36. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
37. [Neuroendocrine cancers of the prostate].
Lépinard V; Dauge-Geffroy MC; Delmas V; Bertrand G; Fondimare A; Fetissof F
Prog Urol; 1993 Feb; 3(1):86-94. PubMed ID: 8485600
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
39. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
40. Primary and pure neuroendocrine tumor of the prostate.
Freschi M; Colombo R; Naspro R; Rigatti P
Eur Urol; 2004 Feb; 45(2):166-69; discussion 169-70. PubMed ID: 14734001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
